New perspectives on the role of vitiligo in immune responses to melanoma

Oncotarget

Volumn 2, Issue 9, 2011, Pages 684-694

  Byrne, Katelyn T ^a   Turk, Mary Jo ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

CD4 T cells; CD8 T cells; Melanocytes; Melanoma; T cell memory; Vitiligo

Indexed keywords

ALPHA INTERFERON; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN; MONOBENZONE; TUMOR ANTIGEN; CANCER VACCINE;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE MODEL; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; MELANOCYTE; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PATHOGENESIS; SKIN SURGERY; T LYMPHOCYTE; TUMOR IMMUNITY; VIROTHERAPY; VITILIGO; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; REVIEW; SKIN TUMOR;

ANIMALS; AUTOIMMUNITY; CANCER VACCINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; VITILIGO;

EID: 84860334025     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.323     Document Type: Article

References (86)

1. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med. 1982; 156:1755-1766.
2. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev. 2002; 188:122-135.
3. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983; 9:689-696.
4. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987; 123:1053-1055.
5. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2009; 21:409-414.
6. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006; 126:2658-2663.
7. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298:850-854.
8. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001; 19:3477-3482.
9. Byrne KT, Cote AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest. 2011; 121:1797-1809.
10. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364:2119-2127.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-723.
12. Cooper S The first lines of the theory and practice of surgery; including priniciple operations., vol. 1, 7 edn. London: Williard Parker; 1844.
13. Matsuzawa T, Watanabe M, Kondo R. Case of leukoderma in X-Ray portion of patient with Melanosarcoma. Shinshu Med J. 1953; 2:254-258.
14. Karcher K. Systematiesierte Depigmentierung bei strahlenbehandelten Melanomen. Dermatologica. 1960; 120:255-263.
15. Burdick KH, Hawk WA. Vitiligo in a Case of Vaccinia Virus-Treated Melanoma. Cancer. 1964; 17:708-712.
16. Smith JL, Jr., Stehlin JS, Jr. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 1965; 18:1399-1415.
17. Milton GW, McCarthy WH, Carlon A. Malignant melanoma and vitiligo. Australas J Dermatol. 1971; 12:131-142.
18. Gregor RT. Vitiligo and malignant melanoma: a significant association? S Afr Med J. 1976; 50:1447-1449.
19. Nordlund JJ, Lerner AB. Vitiligo and melanoma. Arch Dermatol. 1979; 115:636.
20. Donaldson RC, Canaan SA, Jr., McLean RB, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974; 76:771-778.
21. Copeman PW, Lewis MG, Phillips TM, Elliott PG. Immunological associations of the halo naevus with cutaneous malignant melanoma. Br J Dermatol. 1973; 88:127-137.
22. Pantoja E, Wendth AJ, Beecher TS. Perilesional vitiligo in melanoma. Cutis. 1977; 19:51-53.
23. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol. 1983; 9:696-708.
24. Barnes L, Nordlund JJ. Depigmentation: its significance in patients with melanoma. Clin Dermatol. 1989; 7:66-73.
25. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev. 9:516-520.
26. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007; 6:138-142.
27. Houghton AN. The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes. Prog Clin Biol Res. 1983; 119:199-205.
28. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol. 2006; 90:215-241.
29. Michelsen D. The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma. Med Hypotheses. 2010; 74:67-70.
30. Ram M, Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci. 2007; 1110:410-425.
31. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol. 1988; 90:783-789.
32. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986; 15:978-981.
33. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998; 111:1034-1039.
34. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother. 1994; 38:411-416.
35. Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, Fishman P. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother. 1996; 42:297-302.
36. Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev. 2006; 5:486-492.
37. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993; 177:989-998.
38. Becker JC, Guldberg P, Zeuthen J, Brocker EB, Straten PT. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol. 1999; 113:1033-1038.
39. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001; 117:1464-1470.
40. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000; 192:1637-1644.
41. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 2003; 16:254-260.
42. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2010; 36:292-297.
43. Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA, Krueger JG. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 2011; 6:e18907.
44. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995; 182:1609-1614.
45. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188:277-286.
46. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997; 185:453-459.
47. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res. 2005; 11:8114-8121.
48. Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest. 2006; 116:1382-1390.
49. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198:569-580.
50. Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother. 2009; 32:129-139.
51. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000; 191:1221-1232.
52. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC et al. Tumor-specific Th17- polarized cells eradicate large established melanoma. Blood. 2008; 112:362-373.
53. Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol. 2003; 170:5188-5194.
54. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000; 128:273-280.
55. Engelhorn ME, Guevara-Patino JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med. 2006; 12:198-206.
56. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004; 64:1509-1514.
57. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008; 111:3116-3125.
58. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009; 69:9012-9019.
59. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190:355-366.
60. van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong EC, Reits EA, Drijfhout JW, Bos JD, Melief CJ, Luiten RM. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011; 131:1240-1251.
61. van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One. 2010; 5:e10626.
62. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008; 14:3156-3167.
63. Zhang P, Cote AL, de Vries VC, Usherwood EJ, Turk MJ. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 2007; 67:6468-6476.
64. Redondo P, del Olmo J, Lopez-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007; 127:1673-1680.
65. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007; 117:2197-2204.
66. Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011; 60:671-683.
67. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102:9571-9576.
68. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol. 2007; 179:993-1003.
69. Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol. 2010; 184:1909-1917.
70. Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol. 1993; 151:7284-7292.
71. Le Drean E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. Eur J Immunol. 1995; 25:2732-2736.
72. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010; 207:651-667.
73. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010; 207:637-650.
74. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010; 22:223-230.
75. Cable J, Jackson IJ, Steel KP. Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev. 1995; 50:139-150.
76. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005; 167:835-848.
77. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 2006; 66:3287-3293.
78. Cote AL, Zhang P, O'Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patino JA, Turk MJ. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol. 2011; 186:275-283.
79. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007; 27:393-405.
80. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26:5233-5239.
81. Lerner AB, Nordlund JJ. Should vitiligo be induced in patients after resection of primary melanoma. Arch Dermatol. 1977; 113:421.
82. Vlock DR, DerSimonian R, Kirkwood JM. Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986; 77:1116-1121.
83. Hariharan V, Toole T, Klarquist J, Mosenson J, Longley BJ, Le Poole IC. Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res. 2011; 21:115-126.
84. Patel D, Balderes P, Lahiji A, Melchior M, Ng S, Bassi R, Wu Y, Griffith H, Jimenez X, Ludwig DL, Hicklin DJ, Kang X. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies. 2007; 16:127-136.
85. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354:709-718.
86. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011; 17:896-906.